Social Anxiety Disorder (Social Phobia)

1. Clinical Overview

Definition and Conceptualisation

Social Anxiety Disorder (SAD), also known as Social Phobia, is a chronic psychiatric condition characterised by marked and persistent fear of social or performance situations in which the individual may be exposed to unfamiliar people or possible scrutiny by others. [1] The core psychopathological feature is the fear of negative evaluation—the individual fears acting in a way, or showing anxiety symptoms, that will be humiliating, embarrassing, or lead to rejection. [2]

Unlike transient social nervousness experienced by many, SAD represents a clinically significant disorder with substantial functional impairment across occupational, academic, and interpersonal domains. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and the International Classification of Diseases, 11th Revision (ICD-11) both recognise SAD as a distinct anxiety disorder requiring specific diagnostic criteria and treatment approaches. [1,3]

Epidemiological Significance

SAD represents the third most common mental disorder worldwide after major depressive disorder and alcohol use disorder, with lifetime prevalence estimates ranging from 7% to 13% in Western populations. [4] The disorder typically emerges in early adolescence (median age of onset 13 years) and, without treatment, follows a chronic, unremitting course with mean illness duration of 15-20 years at first clinical presentation. [5] The profound underdiagnosis of SAD—with only approximately 35% of affected individuals ever seeking treatment—represents a significant public health challenge. [6]

Clinical Significance

The clinical importance of SAD extends beyond its high prevalence:

Functional Impairment: SAD causes significant disability in educational attainment (reduced participation, school dropout), occupational functioning (underemployment, inability to present or network), and relationship formation (social isolation, delayed marriage). [7]

Comorbidity Cascade: SAD typically precedes the development of major depression, alcohol use disorder, and other anxiety disorders, serving as a "gateway" condition. Approximately 50-70% of individuals with SAD will develop comorbid major depression during their lifetime. [8]

Economic Burden: The economic costs include both direct healthcare costs and substantial indirect costs through lost productivity, underemployment, and disability benefits. [7]

Treatment Responsiveness: Despite its chronicity, SAD is highly responsive to evidence-based treatments, making early recognition and intervention particularly valuable. [9]

Clinical Pearls

"It's not shyness": Shyness is a temperamental trait that does not cause significant functional impairment. SAD is a psychiatric disorder that prevents individuals from living their lives. The shy person feels awkward at parties but attends; the SAD patient cannot attend, or attends in terror and leaves early, with profound relief mixed with self-criticism.

The Alcohol Trap: Up to 28% of patients with SAD meet criteria for alcohol use disorder. Many patients self-medicate with alcohol to reduce anticipatory anxiety. Always screen: "Do you need a drink before social events?" [10]

Performance-Only Specifier: DSM-5 includes a specifier for performance-only SAD, where fear is restricted to speaking or performing in public. This subtype represents approximately 20% of cases and responds particularly well to beta-blockers. [1]

Early Onset, Late Presentation: The typical patient has suffered for 15-20 years before seeking treatment, having normalised their symptoms as "just my personality." Active screening in primary care is essential.

---

2. Epidemiology

Prevalence and Incidence

Demographic Distribution

Cross-Cultural Considerations

SAD presents across all cultures but with varying presentations:

• Taijin Kyofusho (Japan/Korea): Fear of offending others through one's appearance, gaze, body odour, or blushing—an "other-focused" rather than "self-focused" anxiety pattern
• Western Cultures: Typically self-focused fear of embarrassment or negative evaluation
• Collectivist Cultures: May present more with fears of embarrassing family or group rather than individual humiliation

Risk Factors

Behavioural Inhibition: The Key Precursor

Behavioural inhibition (BI) is a temperamental trait observable in infancy, characterised by heightened reactivity to novel stimuli with withdrawal, distress, and physiological arousal. Approximately 15% of infants show high BI. [13]

• Trajectory: High-BI children are 4-7 times more likely to develop SAD by adolescence
• Neural Correlate: BI is associated with increased amygdala reactivity persisting into adulthood
• Moderation: Positive parenting and social opportunities can buffer the BI-SAD pathway
• Clinical Implication: Identifying high-BI children offers opportunity for preventive intervention

---

3. Aetiology and Pathophysiology

Genetic Architecture

Twin studies demonstrate a heritability of approximately 30-40% for SAD, indicating moderate genetic contribution with substantial environmental influence. [12]

Key Findings:

• Monozygotic twin concordance: 24-30%
• Dizygotic twin concordance: 15-20%
• Shared genetic liability with other anxiety disorders and depression
• No single "SAD gene" identified; likely polygenic architecture

Candidate Genes (research level, not clinically applicable):

• Serotonin transporter gene (5-HTTLPR)
• COMT (catechol-O-methyltransferase)
• RGS2 (regulator of G-protein signalling 2)
• NPSR1 (neuropeptide S receptor 1)

Neurobiological Mechanisms

The Fear Circuitry Model

SAD is understood as a disorder of excessive fear response to social stimuli with inadequate cortical regulation.

1. Amygdala Hyperactivity

The amygdala is the brain's primary threat detection centre. In SAD, functional neuroimaging consistently demonstrates: [16]

• Exaggerated amygdala response to faces (especially negative or ambiguous expressions)
• Heightened response to criticism-related words
• Increased activation during anticipation of social evaluation
• Response magnitude correlates with symptom severity

2. Prefrontal Cortex Hypofunction

The medial prefrontal cortex (mPFC) and ventrolateral prefrontal cortex normally exert top-down inhibitory control over the amygdala:

• SAD shows reduced mPFC activation during emotion regulation
• Impaired functional connectivity between mPFC and amygdala
• Successful treatment (both CBT and pharmacotherapy) normalises this connectivity

3. Insula Hyperactivity

The anterior insula processes interoceptive signals (awareness of bodily states):

• Hyperactivation in SAD leads to excessive awareness of anxiety symptoms (blushing, sweating, tremor)
• This creates a vicious cycle: anxiety symptoms → awareness → more anxiety → more symptoms
• Associated with somatic symptom focus in SAD

Neurotransmitter Systems

Psychological Models

Clark and Wells Cognitive Model (1995)

This is the most influential cognitive model and underpins the most effective CBT protocols: [17]

1. Activation of Negative Beliefs

• Core beliefs: "I am boring," "I am socially incompetent," "People will reject me"
• Conditional assumptions: "If I show anxiety, people will think I'm weak"

2. In-Situation Processing

When entering a social situation, three maladaptive processes occur:

a) Self-Focused Attention: Attention shifts from the external environment (others' actual reactions) to internal monitoring (how anxious am I? Am I blushing?)

b) Safety Behaviours: Actions designed to prevent feared outcomes:

• Avoiding eye contact
• Rehearsing sentences before speaking
• Holding objects tightly to hide tremor
• Speaking quietly or quickly

c) Use of Interoceptive Information: The individual uses internal feelings (rather than external evidence) to infer how they appear to others ("I feel anxious, so I must look ridiculous")

3. Anticipatory Processing

• Before social events: extensive rumination, prediction of negative outcomes
• Mental rehearsal of worst-case scenarios

4. Post-Event Processing

• After social events: "post-mortem" analysis
• Selective recall of perceived failures
• Confirmation of negative beliefs

The Vicious Cycle: These processes prevent disconfirmation of negative beliefs, maintain anxiety, and reinforce avoidance.

Rapee and Heimberg Model (1997)

This model emphasises the role of perceived audience and discrepancy between perceived self-presentation and perceived audience standards: [18]

1. Mental representation of self as seen by audience (usually negative, distorted)
2. Perceived audience expectations (usually excessively high)
3. Discrepancy between 1 and 2 generates anxiety
4. Physiological symptoms occur, confirming negative self-image

Developmental Pathways

Genetic Vulnerability + Behavioural Inhibition (Temperament)
                          ↓
        Early Childhood (0-5 years)
        - Parental overprotection
        - Limited social exposure
        - Parental modelling of anxiety
                          ↓
        Middle Childhood (6-12 years)
        - Peer difficulties, bullying
        - Academic social demands increase
        - First symptoms of social anxiety
                          ↓
        Adolescence (12-18 years)
        - Peak onset of full SAD
        - Academic/social demands intensify
        - Dating, identity development challenges
        - Possible onset of avoidance behaviours
                          ↓
        Adulthood (without treatment)
        - Chronic course (15-20+ years)
        - Occupational underachievement
        - Relationship difficulties
        - Comorbid depression (50-70%)
        - Comorbid AUD (20-30%)

---

4. DSM-5 Diagnostic Criteria

Core Criteria (DSM-5 300.23 / F40.10)

The DSM-5 criteria for Social Anxiety Disorder are: [1]

Criterion A: Marked fear or anxiety about one or more social situations in which the individual is exposed to possible scrutiny by others.

• Examples: social interactions (conversing, meeting unfamiliar people), being observed (eating or drinking), and performing in front of others (giving a speech)
• Note: In children, the anxiety must occur in peer settings and not just during interactions with adults

Criterion B: The individual fears that they will act in a way or show anxiety symptoms that will be negatively evaluated (i.e., be humiliating or embarrassing; lead to rejection or offend others).

Criterion C: The social situations almost always provoke fear or anxiety.

• Note: In children, the fear or anxiety may be expressed by crying, tantrums, freezing, clinging, shrinking, or failing to speak in social situations

Criterion D: The social situations are avoided or endured with intense fear or anxiety.

Criterion E: The fear or anxiety is out of proportion to the actual threat posed by the social situation and to the sociocultural context.

Criterion F: The fear, anxiety, or avoidance is persistent, typically lasting for 6 months or more.

Criterion G: The fear, anxiety, or avoidance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.

Criterion H: The fear, anxiety, or avoidance is not attributable to the physiological effects of a substance (e.g., drug of abuse, medication) or another medical condition.

Criterion I: The fear, anxiety, or avoidance is not better explained by the symptoms of another mental disorder (see differential diagnosis).

Criterion J: If another medical condition (e.g., Parkinson's disease, obesity, disfigurement from burns or injury) is present, the fear, anxiety, or avoidance is clearly unrelated or excessive.

Performance-Only Specifier

Specify if: Performance only

This specifier applies when the fear is restricted to speaking or performing in public. This is an important distinction: [1]

ICD-11 Criteria Comparison

ICD-11 (6B04) criteria are largely concordant with DSM-5 but use slightly different language: [3]

• Emphasises "marked and excessive fear or anxiety that consistently occurs in one or more social situations"
• Specifically mentions fear of "negative evaluation by others"
• Requires symptoms "for several months"
• Highlights functional impairment

---

5. Clinical Presentation

Cardinal Features

Core Symptom: Fear of negative evaluation in social or performance situations

The fear centres on:

• Being judged as anxious, weak, stupid, boring, or unlikeable
• Saying something embarrassing or inappropriate
• Showing visible signs of anxiety (blushing, trembling, sweating)
• Being rejected, humiliated, or criticized

Feared Situations Taxonomy

Physical Symptoms (Autonomic Manifestations)

The somatic symptoms of SAD are cardinal to the disorder—many patients are as afraid of showing these symptoms as they are of the social evaluation itself:

Cognitive Manifestations

Behavioural Manifestations

Avoidance Behaviours

Safety Behaviours

Safety behaviours are actions taken to prevent feared outcomes. Critically, they maintain the disorder by preventing disconfirmation of negative beliefs:

Patterns of Presentation by Age

Children and Adolescents:

• Crying, tantrums, freezing, clinging
• School refusal or declining academic participation
• Selective mutism (failure to speak in specific settings despite speaking at home)
• Social isolation, difficulty making friends
• May be misidentified as "just shy" or oppositional

Young Adults:

• Academic underperformance despite ability
• Difficulty with presentations, oral examinations
• Limited dating and relationships
• Occupational underachievement
• Social isolation despite available opportunities
• Onset or escalation of alcohol use

Middle-Aged Adults:

• Chronic underemployment
• Career plateau due to avoidance of promotion/visibility
• Established patterns of avoidance
• Comorbid depression often prominent
• May present with depression rather than SAD

Older Adults:

• Less studied population
• May present with social withdrawal attributed to aging
• Comorbid depression and cognitive concerns
• Reduced treatment-seeking

---

6. Mental State Examination

Typical MSE Findings

Risk Assessment Considerations

Always assess:

• Suicidal ideation: Particularly if comorbid depression present; lifetime suicide attempt rate elevated in SAD
• Self-harm: May occur secondary to distress and isolation
• Substance misuse: Alcohol, benzodiazepines, cannabis commonly used as self-medication
• Functional safety: Is avoidance so severe that basic needs (food, housing, healthcare) are at risk?
• Safeguarding: In adolescents, consider impact on development and education

---

7. Differential Diagnosis

Key Differentials

SAD vs Avoidant Personality Disorder: The Spectrum Debate

This is an exam-relevant distinction: [19]

SAD vs Autism Spectrum Disorder

This distinction is clinically crucial and frequently appears in examinations: [20]

Note: Comorbidity is possible—individuals with ASD can develop secondary social anxiety. The key is identifying which is primary.

---

8. Investigations

Clinical Assessment Tools

SAD is a clinical diagnosis made through structured clinical interview. Standardised instruments support diagnosis and monitor treatment response:

Diagnostic Instruments

Symptom Severity Scales

Comorbidity Screening (Essential)

Physical Investigations

Physical investigations are not required to diagnose SAD but may be indicated to exclude organic causes:

---

9. Management

Overview of Treatment Hierarchy

The treatment of SAD follows a stepped-care model aligned with NICE guidelines (CG159): [9]

┌─────────────────────────────────────────────────────────────────────────────┐
│              SOCIAL ANXIETY DISORDER - TREATMENT ALGORITHM                   │
├─────────────────────────────────────────────────────────────────────────────┤
│                                                                             │
│  STEP 1: Recognition, Psychoeducation & Self-Help                           │
│  ├── Validate condition: SAD is common, treatable, not a character flaw    │
│  ├── Explain the cognitive-behavioural model                                │
│  ├── Recommend evidence-based self-help resources                           │
│  └── For mild symptoms with minimal functional impairment                   │
│                                                                             │
│  STEP 2: Low-Intensity Psychological Interventions (IAPT Step 2)            │
│  ├── Supported self-help (CBT-based)                                        │
│  ├── Psychoeducational groups                                               │
│  └── For mild-moderate symptoms                                             │
│                                                                             │
│  STEP 3: High-Intensity Psychological Therapy (IAPT Step 3) - FIRST LINE    │
│  ├── Individual CBT based on Clark model (14-16 sessions)                   │
│  │   - Strongly recommended as FIRST-LINE for all moderate-severe SAD       │
│  └── Group CBT (if individual unavailable)                                  │
│                                                                             │
│  STEP 4: Pharmacotherapy (If CBT unavailable, declined, or failed)          │
│  ├── FIRST-LINE: SSRI (Escitalopram or Sertraline)                          │
│  │   - Start low, titrate; 12-week adequate trial                           │
│  ├── SECOND-LINE: Venlafaxine SNRI (or alternative SSRI)                    │
│  └── Consider: Pregabalin, Phenelzine (specialist, rarely)                  │
│                                                                             │
│  ADJUNCTS / SPECIFIC SITUATIONS:                                            │
│  ├── Beta-blocker (Propranolol) for Performance-Only SAD (PRN)              │
│  ├── Short-term benzodiazepine (AVOID if possible—dependence risk)          │
│  └── Combined CBT + SSRI for severe/treatment-resistant cases               │
│                                                                             │
│  COMORBIDITY:                                                               │
│  ├── Comorbid depression: SSRI addresses both; ensure depression managed    │
│  └── Comorbid AUD: Address alcohol first or concurrently; motivational      │
│                     interviewing; may need specialist addiction input       │
│                                                                             │
└─────────────────────────────────────────────────────────────────────────────┘

Cognitive Behavioural Therapy: The Gold Standard

CBT is the most effective treatment for SAD, with effect sizes superior to pharmacotherapy and more durable effects at follow-up. [9,17]

Clark and Wells Model CBT Protocol

The Clark and Wells model is specifically designed for SAD and represents the most evidence-based approach: [17]

Core Components:

1. Psychoeducation and Formulation

   • Develop individualised cognitive model
   • Explain the maintenance cycle
   • Identify specific negative beliefs, safety behaviours, and processing biases

2. Attention Training

   • Shift from internal self-focused attention to external focus
   • In-session exercises to practice external focus
   • Demonstrates that external focus reduces anxiety symptoms

3. Behavioural Experiments

   • Test specific predictions in real social situations
   • Example: "If I don't rehearse what to say, I will say something stupid"
   • Systematically test beliefs rather than just expose

4. Video Feedback

   • Record patient in social/performance situation
   • Compare their prediction of how they appeared vs. actual video
   • Typically shows dramatic discrepancy—they appear less anxious than felt
   • Powerful disconfirmation of distorted self-image

5. Dropping Safety Behaviours

   • Deliberately eliminate safety behaviours
   • Discover that feared outcome doesn't occur (or is tolerable)
   • Essential for learning; safety behaviours prevent this

6. Addressing Anticipatory and Post-Event Processing

   • Challenge anticipatory rumination before events
   • Interrupt post-event "post-mortem" rumination
   • Shift attention away from negative aspects

7. Graded Exposure (Within Behavioural Experiments)

   • Develop hierarchy of feared situations
   • Approach situations systematically while testing beliefs

Exposure Hierarchy Example

CBT Treatment Parameters

Pharmacotherapy

Pharmacotherapy is recommended when CBT is unavailable, declined, or has not been effective. [9]

First-Line: SSRIs

Key Points:

• Start low, titrate slowly to minimise initial activation/anxiety
• Adequate trial is 12 weeks at therapeutic dose before switching
• Response may take 8-12 weeks; counsel patients accordingly
• Maintenance: continue 12 months after response; high relapse rate on cessation

Second-Line Options

Third-Line / Specialist

Adjunctive / PRN: Beta-Blockers for Performance Anxiety

Mechanism: Blocks peripheral beta-adrenergic effects (tremor, palpitations, sweating); does NOT address cognitive symptoms

Appropriate Use:

• Performance-only SAD specifier
• Occasional performance situations (public speaking, auditions)
• NOT effective for generalised SAD or daily use

Cautions: Asthma, bradycardia, heart block, hypotension

Drugs to Avoid

Pharmacotherapy Duration and Discontinuation

Combined Treatment

For severe SAD or inadequate response to monotherapy:

• Combined CBT + SSRI may be superior to either alone
• Start SSRI, then add CBT once medication partially effective
• Or start CBT and add SSRI if response incomplete

Treatment in Special Populations

Children and Adolescents (CAMHS)

Older Adults

Pregnancy and Breastfeeding

---

10. Complications and Comorbidities

Psychiatric Comorbidity

SAD rarely exists in isolation. Comorbidity is the rule, not the exception: [8]

Functional Complications

Selective Mutism: A Childhood Variant

Definition: Consistent failure to speak in specific social situations (e.g., school) despite speaking normally at home.

Association: Strongly associated with SAD; may represent childhood manifestation.

Key Features:

• Onset typically early childhood (before age 5)
• Most commonly affects school setting
• Child speaks normally at home with family
• Not due to communication disorder or ASD

Treatment:

• Behavioural approaches with graduated exposure ("brave talking")
• Stimulus fading and shaping techniques
• School and parent involvement essential
• SSRIs if severe and behavioural approach insufficient

Medical Comorbidities

• Cardiovascular: Chronic stress may contribute to hypertension, cardiovascular risk
• Gastrointestinal: Functional GI disorders (IBS-like symptoms) common
• Sleep: Insomnia, particularly with anticipatory anxiety

---

11. Prognosis and Outcomes

Natural History

Without treatment, SAD follows a chronic, unremitting course: [5]

• Spontaneous remission: Rare (less than 20% in community studies)
• Duration at presentation: Mean 15-20 years
• Trajectory: Typically begins in early adolescence and persists throughout life if untreated
• Worsening factors: Comorbid depression, alcohol use, life stressors

Treatment Outcomes

Prognostic Factors

Long-Term Follow-Up

• Patients who respond to CBT typically maintain gains at 1-2 year follow-up
• Skills learned in CBT are protective against relapse
• Medication discontinuation carries high relapse risk; may need long-term treatment
• Periodic "booster" sessions can reinforce CBT gains

---

12. Prevention and Screening

Primary Prevention

Targeting Behavioural Inhibition:

• Programs like "Cool Little Kids" target high-BI children with parent training
• Aim: Reduce parental overprotection; increase child's social exposure; build resilience
• Evidence: Can reduce trajectory to anxiety disorders

School-Based Programs:

• Universal anxiety prevention programs
• Social skills training
• Anti-bullying interventions

Screening in Primary Care

Who to Screen:

• Patients presenting with depression (ask about preceding social anxiety)
• Patients requesting alcohol or benzodiazepines for "nerves"
• Young people with academic/occupational underperformance
• Patients who frequently cancel or fail to attend appointments (avoidance)
• Parents of very shy, inhibited children

Quick Screen Questions:

1. "Do you avoid social situations because of fear or embarrassment?"
2. "Does fear of embarrassment or being judged stop you from doing things you want to do?"
3. "Do you need alcohol to cope with social events?"

Validated Screen: SPIN (Social Phobia Inventory) - 17 items, self-report, cutoff ≥19

---

13. Key Guidelines and Evidence

Major Clinical Guidelines

Landmark Studies

1. Clark et al. (2003) - Cognitive Therapy vs Fluoxetine

• Design: RCT comparing CT, fluoxetine + self-exposure, and placebo
• Finding: CT superior to fluoxetine; effects maintained at 12 months
• Impact: Established specific cognitive therapy as gold standard
• Citation: [17]

2. Mayo-Wilson et al. (2014) - Network Meta-Analysis

• Design: Systematic review and network meta-analysis of psychological and pharmacological treatments
• Finding: Individual CBT was most effective psychological treatment; SSRIs most effective pharmacotherapy
• Impact: Informed NICE guideline recommendations
• Citation: [9]

3. Blanco et al. (2010) - CBT vs Phenelzine vs Combined

• Design: RCT comparing CBT, phenelzine, combined, and placebo
• Finding: Phenelzine response fastest; CBT effects most durable; combined not superior to monotherapy
• Impact: Supported monotherapy approach for most patients

4. Heimberg et al. (1998) - Cognitive Behavioral Group Therapy

• Design: RCT of CBGT vs educational supportive group therapy
• Finding: CBGT superior; maintained at 5-year follow-up
• Impact: Established group CBT efficacy

---

14. Exam-Focused Content

Common Viva Questions and Model Answers

Q1: "Tell me about Social Anxiety Disorder."

Model Answer: "Social Anxiety Disorder is a common psychiatric condition characterised by marked and persistent fear of social situations in which the individual may be exposed to scrutiny by others. The core psychopathology is fear of negative evaluation—the individual fears acting in a way that will be humiliating or embarrassing. It affects approximately 7-12% of the population over their lifetime, making it the third most common mental disorder. Onset is typically in early adolescence, and without treatment, the course is chronic and unremitting. The key differential diagnoses include normal shyness, which does not cause functional impairment; generalised anxiety disorder, where worry is diffuse rather than focused on evaluation; and avoidant personality disorder, which may represent the severe end of the same spectrum. First-line treatment is cognitive behavioural therapy based on the Clark and Wells model, which has response rates of 50-70% with durable effects. SSRIs such as escitalopram or sertraline are second-line if CBT is unavailable or ineffective."

Q2: "How would you differentiate SAD from autism spectrum disorder?"

Model Answer: "This is an important distinction. In Social Anxiety Disorder, the core problem is fear of negative evaluation—the individual understands social cues but is afraid of being judged. In Autism Spectrum Disorder, the core problem is impaired social cognition—the individual has difficulty reading social cues, understanding non-verbal communication, and engaging in reciprocal conversation. A patient with SAD typically desires social connection but avoids it due to fear, whereas a patient with ASD may have reduced desire for social connection or a qualitatively different form of relating. Eye contact in SAD is avoided due to fear; in ASD it may be avoided due to discomfort or not recognising its importance. Response to treatment also differs: CBT reduces anxiety in SAD; social skills training may help ASD but doesn't address the underlying neurodevelopmental difference. Of course, comorbidity is possible—an individual with ASD may develop secondary social anxiety."

Q3: "A 16-year-old refuses to attend school due to fear of being called on in class. What is your approach?"

Model Answer: "This presentation is consistent with Social Anxiety Disorder, though I would want to exclude depression with school avoidance, specific phobia, and truancy with another motivation. My assessment would include a thorough psychiatric history, screening for comorbid depression with PHQ-9 and anxiety with GAD-7, assessment of substance use, and a risk assessment. I would also want collateral history from parents and school. If SAD is confirmed, first-line treatment is individual CBT adapted for adolescents. I would involve the school to implement reasonable accommodations such as not forcing oral answers initially, small group work, and graduated reintroduction of feared situations as part of an exposure hierarchy. Parent work is important to reduce accommodation of avoidance. If CBT is unavailable or ineffective, I would consider an SSRI such as fluoxetine or sertraline, with appropriate monitoring in under-18s. This patient should be referred to CAMHS."

Q4: "What is the cognitive model of SAD and how does it inform treatment?"

Model Answer: "The Clark and Wells cognitive model proposes that SAD is maintained by a vicious cycle of cognitive and behavioural processes. When entering a social situation, individuals with SAD shift attention inwards to monitor their own anxiety symptoms rather than attending to external cues. They engage in safety behaviours—actions designed to prevent feared outcomes such as avoiding eye contact or speaking quietly. They use internal feelings to infer how they appear to others, creating a distorted self-image. Before social situations, anticipatory processing involves predicting negative outcomes; afterwards, post-event processing involves ruminating on perceived failures. These processes prevent disconfirmation of negative beliefs and maintain the disorder. Treatment based on this model specifically targets each component: attention training shifts focus externally; behavioural experiments test specific predictions; video feedback challenges distorted self-image by showing patients they appear less anxious than they feel; and deliberate dropping of safety behaviours allows natural habituation."

Q5: "When would you use a beta-blocker for social anxiety?"

Model Answer: "Beta-blockers, specifically propranolol at 10-40mg given 30-60 minutes before an event, are appropriate for the Performance-Only specifier of Social Anxiety Disorder. This subtype, representing about 20% of SAD cases, is characterised by fear restricted to speaking or performing in public, with otherwise intact social function. Beta-blockers work by blocking peripheral adrenergic effects—reducing tremor, palpitations, and sweating. They do NOT address cognitive symptoms. They are used PRN for occasional performance situations such as public speaking, auditions, or presentations. They are NOT effective for generalised SAD affecting multiple social situations, and would not be used as daily treatment. Contraindications include asthma, bradycardia, and hypotension."

Common Exam Mistakes

Key Numbers to Remember

---

15. Patient Information

What is Social Anxiety?

Social Anxiety Disorder is much more than being shy. It is an intense, persistent fear of social situations where you might be judged, embarrassed, or humiliated. This fear is so strong that it can stop you from doing everyday things like talking to people, eating in public, or giving presentations.

Social anxiety is one of the most common mental health conditions, affecting about 1 in 10 people at some point in their lives. It usually starts in the teenage years and can last a long time if not treated—but the good news is that it is very treatable.

What Causes Social Anxiety?

Social anxiety develops from a combination of factors:

• Genetics: It can run in families
• Brain chemistry: The part of the brain that detects danger (the amygdala) may be overactive
• Life experiences: Bullying, embarrassing events, or critical parenting can contribute
• Personality: Being naturally shy or cautious as a child can be a starting point

It is NOT a character flaw or weakness.

What Are the Symptoms?

Physical symptoms (your body's alarm system):

• Blushing, trembling, sweating
• Racing heart, "butterflies"
• Dry mouth, mind going blank

Thoughts:

• "Everyone is watching me"
• "I'll say something stupid"
• "They think I'm boring"

Behaviours:

• Avoiding social situations
• Leaving events early
• Needing alcohol to cope
• Spending hours worrying before and analysing after social events

How is it Treated?

1. Talking Therapy (CBT): The most effective treatment. A therapist helps you:

• Understand your anxiety patterns
• Challenge unhelpful thoughts
• Gradually face feared situations at your own pace
• Learn that the feared outcomes usually don't happen

2. Medication: Antidepressants (SSRIs) can reduce anxiety. They are helpful if therapy isn't available or isn't enough alone.

3. Self-Help: Books and online programs based on CBT principles can help, especially for milder symptoms.

Will I Always Have This?

Many people with social anxiety recover or significantly improve with treatment. CBT teaches skills that last a lifetime. The key is to seek help rather than suffering in silence—most people wait too long before getting treatment.

Self-Help Resources

---

16. Quality Standards and Audit Criteria

Clinical Standards

---

17. References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.

2. Stein MB, Stein DJ. Social anxiety disorder. Lancet. 2008;371(9618):1115-1125. doi:10.1016/S0140-6736(08)60488-2

3. World Health Organization. International Classification of Diseases. 11th Revision. Geneva: WHO; 2019.

4. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169-184. doi:10.1002/mpr.1359

5. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602. doi:10.1001/archpsyc.62.6.593

6. Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):629-640. doi:10.1001/archpsyc.62.6.629

7. Wittchen HU, Fuetsch M, Sonntag H, Müller N, Liebowitz M. Disability and quality of life in pure and comorbid social phobia. Findings from a controlled study. Eur Psychiatry. 2000;15(1):46-58. doi:10.1016/S0924-9338(00)00211-X

8. Chartier MJ, Walker JR, Stein MB. Considering comorbidity in social phobia. Soc Psychiatry Psychiatr Epidemiol. 2003;38(12):728-734. doi:10.1007/s00127-003-0720-6

9. Mayo-Wilson E, Dias S, Mavranezouli I, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):368-376. doi:10.1016/S2215-0366(14)70329-3

10. Book SW, Thomas SE, Randall PK, Randall CL. Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder. J Anxiety Disord. 2008;22(2):310-318. doi:10.1016/j.janxdis.2007.03.001

11. Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;(420):21-27. doi:10.1111/j.1600-0047.2004.00327.x

12. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry. 2001;158(10):1568-1578. doi:10.1176/appi.ajp.158.10.1568

13. Clauss JA, Blackford JU. Behavioral inhibition and risk for developing social anxiety disorder: a meta-analytic study. J Am Acad Child Adolesc Psychiatry. 2012;51(10):1066-1075.e1. doi:10.1016/j.jaac.2012.08.002

14. Spence SH, Rapee RM. The etiology of social anxiety disorder: An evidence-based model. Behav Res Ther. 2016;86:50-67. doi:10.1016/j.brat.2016.06.007

15. McCabe RE, Antony MM, Summerfeldt LJ, Liss A, Swinson RP. Preliminary examination of the relationship between anxiety disorders in adults and self-reported history of teasing or bullying experiences. Cogn Behav Ther. 2003;32(4):187-193. doi:10.1080/16506070310005051

16. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry. 2007;164(10):1476-1488. doi:10.1176/appi.ajp.2007.07030504

17. Clark DM, Ehlers A, McManus F, et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol. 2003;71(6):1058-1067. doi:10.1037/0022-006X.71.6.1058

18. Rapee RM, Heimberg RG. A cognitive-behavioral model of anxiety in social phobia. Behav Res Ther. 1997;35(8):741-756. doi:10.1016/S0005-7967(97)00022-3

19. Reichborn-Kjennerud T, Czajkowski N, Torgersen S, et al. The relationship between avoidant personality disorder and social phobia: a population-based twin study. Am J Psychiatry. 2007;164(11):1722-1728. doi:10.1176/appi.ajp.2007.06101764

20. Spain D, Sin J, Linder KB, McMahon J, Happé F. Social anxiety in autism spectrum disorder: A systematic review. Res Autism Spectr Disord. 2018;52:51-68. doi:10.1016/j.rasd.2018.04.007

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. If you are struggling with anxiety, please speak to a healthcare professional.